|
gptkbp:instanceOf
|
gptkb:synthetic_anabolic-androgenic_steroid
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:bannedIn
|
gptkb:World_Anti-Doping_Agency
|
|
gptkbp:CASNumber
|
65-04-3
|
|
gptkbp:chemicalFormula
|
C20H30O2
|
|
gptkbp:derivative_of
|
1-testosterone
|
|
gptkbp:drugClass
|
gptkb:anabolic_steroid
gptkb:androgen
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstDescribed
|
1960s
|
|
gptkbp:halfLife
|
gptkb:unknown
|
|
gptkbp:IUPACName
|
17β-hydroxy-17α-methylandrost-1-en-3-one
|
|
gptkbp:KEGGID
|
C19697
|
|
gptkbp:legalStatus
|
Schedule III controlled substance
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
302.451 g/mol
|
|
gptkbp:otherName
|
gptkb:M1T
gptkb:17α-methyl-1-testosterone
|
|
gptkbp:parent_compound
|
testosterone
|
|
gptkbp:PubChem_CID
|
9046
9415
CHEMBL190901
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
hepatotoxicity
gynecomastia
suppression of natural testosterone production
|
|
gptkbp:structureType
|
17α-alkylated steroid
|
|
gptkbp:UNII
|
1Y1FQ5Y7F7
|
|
gptkbp:usedFor
|
performance enhancement
|
|
gptkbp:bfsParent
|
gptkb:M1T
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
methyl-1-testosterone
|